$MRNA

AI Analysis

Generated on May 11, 2026

AI Score
42/ 100
Sell$MRNA

Moderna Inc.

$MRNANASDAQHealthcareLarge-Cap

Moderna develops mRNA-based vaccines and therapeutics including COVID-19 vaccines and a cancer pipeline.

Market Cap
$18.0B
Revenue (TTM)
$6.8B
-40.0%
Net Income (TTM)
-$3.5B
N/A
EPS (TTM)
-$9.00
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$65-$170
Beta
1.82
Dimension Scores
Fundamental
35
Technical
42
Sentiment
48
Risk / Reward
40
Momentum
48
FundTechSentRiskMome
Financial Health
Profitability
40weak
Growth
51weak
Liquidity
48strong
Solvency
37moderate
Efficiency
33moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $MRNA

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.